Moderna Inc

-21.22 (-4.93%)
5:03:02 PM EDT: $409.00 +0.08 (+0.02%)
Products, Regulatory

Moderna Announces Significant Advances Across Industry-Leading Mrna Portfolio At 2021 Research And Development Day

Published: 09/09/2021 12:21 GMT
Moderna Inc (MRNA) - Moderna Announces Significant Advances Across Industry-leading Mrna Portfolio at 2021 Research and Development Day.
Moderna Inc - Interim Phase 1 Data From Rsv Vaccine Candidate in Older Adults Significantly Boosted Neutralizing Antibody Titers Above Baseline.
Moderna Inc - New Pediatric Combination Development Candidate for Rsv + Hmpv Vaccine.
Moderna Inc - New Development Candidate for Combination Respiratory Covid-19 Booster + Seasonal Flu Booster Vaccine.
Moderna Inc - Company Continues to Scale With 37 Programs in Development, Including 22 in Ongoing Clinical Studies.
Moderna Inc - Phase 2 Randomized, Placebo-controlled Study of Personalized Cancer Vaccine Fully Enrolled; Primary Endpoint is Recurrence Free Survival at 12 Months.
Moderna Inc - Enrollment of First Cohort in Propionic Acidemia (mrna-3927) Phase 1/2 Paramount Study is Complete.
Moderna Inc - Moderna Genomics (mgx) Will Leverage Moderna's Current Mrna and Lipid Nanoparticle (lnp) Platform.
Moderna Inc - Announces a Cash Position As of August 31, 2021 of About $15 Billion.